Gilead teams up with insitro for experimental NASH treatments

Gilead Sciences Inc said on Tuesday it will partner with privately held insitro to develop therapies for a fatty liver disease called non-alcoholic steatohepatitis (NASH), as the drugmaker tries to overcome its recent setback in developing NASH treatments.

Cholera cases rise in Kenya's capital, top hospital says

The Kenyan capital has experienced a jump in cholera cases, one of the city's top hospitals said on Tuesday, adding that eight of its own staff had been infected by the disease.

China urges large pig farms to test for African swine fever

China will allow large-scale pig farms and breeding farms to test for African swine fever in a bid to help early detection of the disease, overturning an earlier prohibition on commercial firms carrying out their own testing.

U.S. measles cases surge nearly 20 percent in early April, CDC says

The number of confirmed cases of measles in the United States this year jumped by nearly 20 percent in the week ended April 11, in the country's second-worst outbreak in nearly two decades, federal health officials reported on Monday.

Financial scam victims have higher risk of Alzheimer's

(Reuters Health) - Older adults who are victims of financial scams may be more likely to develop dementia and Alzheimer's disease than elderly people who don't get tricked by scammers, a small U.S. study suggests.

New 'added sugars' labeling could save money and improve health

(Reuters Health) - The Food and Drug Administration's new mandatory rules requiring labels on all packaged foods and drinks to indicate the presence of so-called added sugars could have substantial health and cost saving benefits in the United States over the next two decades, a new study suggests.

First-year trainee doctors spend little time on patient care

(Reuters Health) - Over a typical 24-hour shift, first year residents training in internal medicine spend just three hours on direct patient care and only 1.8 hours on education, a U.S. study suggests.

Amgen sets $21,900 annual price for new Evenity bone drug

Amgen Inc on Monday set the U.S. list price for its new Evenity osteoporosis drug at $1,825 a month, or $21,900 for a full 12-month course of injections.

Cannabis users may need more anesthesia for surgery

(Reuters Health) - People who regularly use cannabis may need more than twice the usual dose of anesthesia for surgery, a U.S. study suggests.

Catalent seeks slice of gene therapy market with Paragon buy

Contract drugmaker Catalent Inc said on Monday it would buy privately held Paragon Bioservices Inc for $1.2 billion in cash, bolstering its capabilities to make gene therapy drugs for its biotech clients.

Measles cases rose nearly four-fold in first quarter 2019: WHO

The number of measles cases worldwide nearly quadrupled in the first quarter of 2019 to 112,163 against the same period last year, the World Health Organization (WHO) said on Monday, citing provisional data.

Related Videos

Introducing the all-new
Reuters News app

The new Reuters News app is here, redesigned from the ground up to fit your busy life.

Get it now on iOS